Cantargia AB (publ) (STO:CANTA)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 962.13M |
| Revenue (ttm) | 316.70M |
| Net Income (ttm) | 146.97M |
| Shares Out | 248.61M |
| EPS (ttm) | 0.58 |
| PE Ratio | 6.67 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,804,433 |
| Average Volume | 1,530,340 |
| Open | 3.950 |
| Previous Close | 3.870 |
| Day's Range | 3.830 - 4.040 |
| 52-Week Range | 1.000 - 6.590 |
| Beta | 1.76 |
| RSI | 44.63 |
| Earnings Date | May 19, 2026 |
About Cantargia AB
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops... [Read more]
Financial Performance
Financial StatementsNews
Cantargia AB (FRA:7V3) Q4 2025 Earnings Call Highlights: A Year of First-Time Profitability ...
Cantargia AB (FRA:7V3) Q4 2025 Earnings Call Highlights: A Year of First-Time Profitability Amidst Ongoing Challenges
Q4 2025 Cantargia AB Earnings Call Transcript
Q4 2025 Cantargia AB Earnings Call Transcript
Cantargia AB Earnings Call Transcript: Q4 2025
Advanced nadunolimab to pivotal trial readiness in PDAC, reported strong financials with first-ever annual profit, and secured a robust cash runway into 2028. Investor interest in PDAC is rising, and key milestones are targeted for 2026.
Cantargia AB (FRA:7V3) Q3 2025 Earnings Call Highlights: First-Ever Profits and Promising ...
Cantargia AB (FRA:7V3) Q3 2025 Earnings Call Highlights: First-Ever Profits and Promising Cancer Treatment Results
Q3 2025 Cantargia AB Earnings Call Transcript
Q3 2025 Cantargia AB Earnings Call Transcript
Cantargia AB Earnings Call Transcript: Q3 2025
Q3 2025 saw a major financial boost from the Otsuka deal, resulting in first-ever reported profits and a strengthened cash position. Nadunolimab in PDAC remains the strategic focus, with a pivotal trial planned for mid-2026, while new pipeline assets advance in preclinical stages.
Cantargia AB Transcript: Life Science Summit 2025
Nadunolimab, a pivotal-ready antibody for PDAC, showed improved survival in patients with high IL1RAP levels and received FDA fast-track status. Financial flexibility from a major partnership supports further development, with a pivotal trial and biomarker-driven strategy planned.
Cantargia AB Transcript: Investing in Life Science 2025
Nadunolimab advances as a lead IL-1RAP antibody in cancer, with FDA fast-track status and a focus on high IL-1RAP patients. A major Otsuka deal provides financial flexibility, while ongoing trials and a new CEO's strategic focus aim to maximize the asset's potential.
Cantargia AB Earnings Call Transcript: Q2 2025
Otsuka acquired CAN10 for $33M upfront plus up to $580M in milestones, with deal closing in Q3 2025. Operating expenses fell 10% year-over-year, and a new CEO, Dr. Hilde Steineger, was appointed. Nadunolimab received FDA fast-track in PDAC, and the company expects improved financial stability.
Cantargia AB Earnings Call Transcript: Q1 2025
Strong clinical progress with CANTEN and nadunolimab, including phase 1 completion and new indications, drove higher R&D costs and operating losses. Cash runway extends into Q4 2025, but additional funding is needed amid challenging biotech market conditions.
Cantargia AB Earnings Call Transcript: Q4 2024
Leadership transition brings focus on value creation and transactions for lead assets. Operating expenses fell 42% year-over-year, with a strengthened cash position post-rights issue. Multiple clinical milestones and potential partnerships are expected in 2024–2025.
Cantargia AB (FRA:7V3) Q3 2024 Earnings Call Highlights: Strategic Shifts and Financial Updates
Cantargia AB (FRA:7V3) Q3 2024 Earnings Call Highlights: Strategic Shifts and Financial Updates
Q3 2024 Cantargia AB Earnings Call Transcript
Q3 2024 Cantargia AB Earnings Call Transcript
Cantargia AB Earnings Call Transcript: Q3 2024
Progress in both oncology and immunology programs, with strong clinical data and FDA clearance for a leukemia study. Lower R&D and G&A expenses led to a SEK 122 million YTD loss; a rights issue aims to extend the cash runway to mid-2026 and fund key milestones.
Cantargia AB Earnings Call Transcript: Q2 2024
Two clinical programs advanced with strong safety and efficacy signals; operating expenses reduced 39% year-over-year. Financing remains a key focus, with available funds expected to last into 2025 and major trials contingent on securing additional capital.